Heartflow (NASDAQ:HTFL) CEO John C.M. Farquhar Sells 9,725 Shares

Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) CEO John C.M. Farquhar sold 9,725 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $25.00, for a total transaction of $243,125.00. Following the completion of the sale, the chief executive officer directly owned 571,725 shares of the company's stock, valued at $14,293,125. The trade was a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

John C.M. Farquhar also recently made the following trade(s):

• On Tuesday, March 10th, John C.M. Farquhar sold 12,837 shares of Heartflow stock. The shares were sold at an average price of $22.66, for a total transaction of $290,886.42.
• On Tuesday, February 10th, John C.M. Farquhar sold 22,562 shares of Heartflow stock. The stock was sold at an average price of $27.46, for a total transaction of $619,552.52.

Heartflow Price Performance

NASDAQ:HTFL opened at $26.02 on Friday. The business's 50-day moving average is $26.86 and its two-hundred day moving average is $30.41. The firm has a market capitalization of $2.23 billion and a PE ratio of -14.38. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.

Institutional Trading of Heartflow

---

---

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new stake in Heartflow during the fourth quarter valued at approximately $27,000. TFC Financial Management Inc. acquired a new position in shares of Heartflow in the 3rd quarter worth approximately $40,000. Russell Investments Group Ltd. bought a new stake in shares of Heartflow in the 4th quarter valued at approximately $45,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in shares of Heartflow during the 4th quarter valued at approximately $99,000.

Wall Street Analyst Weigh In

HTFL has been the topic of several recent research reports. Weiss Ratings reissued a "sell (d)" rating on shares of Heartflow in a research report on Monday, December 29th. JPMorgan Chase & Co. dropped their price objective on shares of Heartflow from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday. Wells Fargo & Company reduced their target price on shares of Heartflow from $38.00 to $35.00 and set an "overweight" rating on the stock in a research report on Thursday. Finally, Canaccord Genuity Group raised their price target on shares of Heartflow from $40.00 to $43.00 and gave the company a "buy" rating in a report on Thursday. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $37.67.

Check Out Our Latest Stock Analysis on Heartflow

Heartflow News Summary

Here are the key news stories impacting Heartflow this week:

• Positive Sentiment: Q4 revenue beat and strong top‑line growth — HeartFlow reported revenue of $49.13M vs consensus $46.58M, up ~40.5% year‑over‑year, signaling accelerating adoption and top-line momentum. MarketBeat: Q4 results & transcript
• Positive Sentiment: Bullish analyst move — Canaccord raised its price target to $43 and maintained a Buy rating, implying a sizable upside and providing supportive institutional sentiment. Benzinga: Canaccord price target raise
• Neutral Sentiment: Analysts cut targets but stayed positive — JPMorgan lowered its PT from $40 to $35 but kept an Overweight rating, signaling confidence in the business even while trimming valuation assumptions. Benzinga: JPMorgan PT change
• Neutral Sentiment: Wells Fargo also trimmed its PT (from $38 to $35) but maintained an Overweight rating, another sign of cautious optimism. Benzinga: Wells Fargo PT change
• Neutral Sentiment: Independent analysis available — Seeking Alpha published a piece reviewing HeartFlow’s strategy and growth opportunities; useful for investors analyzing the longer‑term thesis. Seeking Alpha: HeartFlow: Getting Into The Flow
• Negative Sentiment: EPS miss and continued losses — HeartFlow reported GAAP EPS of ($0.29) vs consensus ($0.16), missing estimates and underscoring margin pressure and ongoing unprofitability (PE remains negative). MarketBeat: EPS miss / earnings details
• Negative Sentiment: Valuation and trend considerations — Despite the rally, the stock remains below its 50‑day and 200‑day moving averages and carries a wide range of analyst targets, indicating continued volatility and mixed near‑term sentiment. Benzinga: HTFL earnings & estimates

About Heartflow

(Get Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

Read More

• Five stocks we like better than Heartflow

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].